The discovery of the first mRNA-stabilizing substance could pave the way for groundbreaking advancements in the development ...

Moderna is focusing on respiratory vaccines to sustain revenue streams amid COVID-19 declines. See more on MRNA stock and its ...

Study reveals single-chain mRNA vaccines confer 100% protection against lethal mpox challenge in mice, marking a significant ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...

The jab uses mRNA technology to tell the immune system to recognise a ‘foreign’ protein on viruses and mount an attack.

Northwestern filed a lawsuit against Moderna Wednesday alleging the company misused the University’s patented lipid ...

In one of our recent articles about 10 High Growth Non-Tech Stocks That Are Profitable in 2024, we talked about how the US ...

He said: “The UK is leading the way to develop a world-first vaccine for this vomiting bug, starting with this innovative ...

Revaccination at 12 months with the investigational respiratory syncytial virus (RSV) vaccine mRNA-1345 is well tolerated and supported for eligible older adults, according to study results presented ...

On Monday, Moderna Inc (MRNA) stock saw a decline, ending the day at $53.8 which represents a decrease of $-0.30 or -0.55% from the prior close of $54.1. The stock opened at $53.82 and touched a low ...

The UK Government has recommended offering a COVID-19 booster vaccination in autumn, 2024, to individuals at high risk of ...

Wes Streeting said the virus places the health service under 'huge strain' every winter and costs taxpayers around ...